author-photo

Jianning Yang

27

Papers

555

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (27)
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.

2015 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (68)
Design and Test of the Semi-Automatic Test-Bed with Inclined Belt of Garlic Transplanting Machine

2015 American Journal of Plant Sciences
Show All
- Source
- Cite
- Save
Citations (0)
ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.

2014 Journal of Clinical Pharmacy and Therapeutics
Show All
- Source
- Cite
- Save
Citations (5)
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (45)
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

2014 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (59)
The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (15)
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

2014 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (33)
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (82)